Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers

The objective of this study is to demonstrate the primary hypothesis that, in patients with chronic and acute coronary syndromes requiring percutaneous coronary intervention (PCI), the novel sirolimus-ascorbic acid eluting stent (D+Storm Novonix) is non-inferior to the standard treatment, the everolimus-eluting stent (Synergy XD), with respect to the incidence of target lesion failure (TLF) at 1 year after treatment, where TLF is defined as a composite of cardiovascular death, target vessel myocardial infarction, and clinically driven target-lesion revascularization.

NCT Number	NCT07566091
Lead Sponsor	Jung-min Ahn Collaborators: The CardioVascular Research Foundation (CVRF)
Conditions	Coronary Artery Disease
Enrollment	2,034 participants
Start Date	2026-06-15
Primary Completion	2027-06-15 (estimated)
Study Completion	2028-06-15 (estimated)
Updated on ClinicalTrials.gov	2026-05-04